Please enable JavaScript or talk to your local administrator to get JavaScript enabled.


Bladder cancer chemotherapy potentiation with a multiprong arachidonic acid pathway modulator

Funder: National Cancer Institute

Funding period
USD 300 K
Funding amount
Abstract A combination of cytotoxic chemotherapeutic drugs, such as gemcitabine and cisplatin (GC), is part of the standard of care for advanced bladder cancer. Neoadjuvant GC treatment can induce complete remission (no evidence of viable cancer cells), but less than 40% of patients respond and the regimen is toxic. Thus, there remains an unmet medical need to develop less toxic and more effective chemotherapy options for bladder cancer. We are developing an orally bioavailable drug candidate called PTUPB which has such properties. The compound has anti-inflammatory and anti-angiogenic mechanisms of action as demonstrated in several rodent models of metabolic syndrome and cancer. PTUPB potentiates cisplatin and GC efficacy in a bladder cancer mouse PDX models. We propose to extend this work to include determination of dose-dependent PK and anti-tumor activity and preliminary toxicity assessment for PTUPB as a single agent and in combination with GC therapy in an established patient derived xenograft (PDX) mouse model of bladder cancer. Progression free and overall survival will be assessed along with pharmacokinetic profiling, blood panels and histology assessment of selected tissues.
Similar projects All >
Sorted by: Start Date
Project list item
CD40 agonism for the treatment of bladder cancer

National Cancer Institute to CHRISTOPHER STUART GARRIS

USD 64,554
2020 - 2023
Project list item
Combatting Bladder Cancer by Inducing Epithelial Turnover

National Cancer Institute to SOMAN N ABRAHAM

USD 372,404
2019 - 2021
Project list item
Novel recombinant BCG for immunotherapy of bladder cancer

National Cancer Institute to BORIS SHOR

USD 290,014
2018 - 2020
Project list item
Prevention of Urinary Bladder Cancer with Two Clinically-Ready Agents (Everolimus andNaproxen) When Administered in Combination

National Cancer Institute to CLINTON GRUBBS

USD 709,567
2018 - 2021
Project list item
Role of B-arrestins in bladder cancer progression and response to chemotherapy

United States Department of Veterans Affairs to BAL L LOKESHWAR

2018 - 2022



    1112 Oncology and Carcinogenesis

  • RCDC


  • RCDC

    Orphan Drug

  • RCDC

    Rare Diseases

  • RCDC

    Urologic Diseases




    5.1 Pharmaceuticals


    6.1 Pharmaceuticals

  • Health Research Areas


  • Broad Research Areas

    Clinical Medicine and Science